RegeneRx
  |   Contact Us


News & Events

News Release Archive
Articles
DateTitle 
04/18/12Scientists Report that Process of Converting Non-Beating Heart Cells into Functional, Beating Heart Cells is Enhanced Using Thymosin Beta 4 in Conjunction with Gene TherapyPrinter Friendly Version
04/09/12RegeneRx Receives Four New Patents and Allowances in Mexico and IsraelPrinter Friendly Version
03/27/12RegeneRx and Lee's Pharmaceutical (HK) Sign Term Sheet for Development of RegeneRx Product Candidates in China, Hong Kong and MacauPrinter Friendly Version
03/27/12RegeneRx and Lee’s Pharmaceutical (HK) Sign Term Sheet for Development of RegeneRx Product Candidates in China, Hong Kong and MacauPrinter Friendly Version
03/20/12New Data on Thymosin Beta 4 Reported at Third International Symposium on Thymosins in Health and DiseasePrinter Friendly Version
02/15/12Researchers Show TB4 Provides Both Neuroprotection and Neurorestoration after Traumatic Brain InjuryPrinter Friendly Version
02/01/12RegeneRx Engages Investment Bankers to Assist in Evaluating and Exploring Strategic OpportunitiesPrinter Friendly Version
01/09/12RegeneRx Issued Major U.S. Heart PatentPrinter Friendly Version
01/05/12RegeneRx Receives Clinical Study Report for Phase 2 Dry Eye TrialPrinter Friendly Version
12/28/11Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye DropPrinter Friendly Version
11/29/11RegeneRx Receives Notice of Allowance on U.S. Patent for Skin Protection and RepairPrinter Friendly Version
11/17/11RegeneRx Receives Notice of Allowance on Two Cardiac-Related Patent ApplicationsPrinter Friendly Version
11/04/11RegeneRx Reports Positive Data with RGN-259 in Phase 2 Dry Eye TrialPrinter Friendly Version
11/04/11RegeneRx Answers Questions Regarding Phase 2 Dry Eye TrialPrinter Friendly Version
10/20/11RegeneRx Phase 2 Dry Eye Data Expected Week of October 31stPrinter Friendly Version
10/06/11RegeneRx Receives Notice of Allowance for Key U.S. Heart PatentPrinter Friendly Version
09/23/11RegeneRx Announces Completion of Patient Treatment in RGN-259 Phase 2 Dry Eye TrialPrinter Friendly Version
09/07/11RegeneRx President and CEO to Speak at Rodman & Renshaw 13th Annual Global Investment ConferencePrinter Friendly Version
08/24/11Patient Enrollment Completed in Phase 2 Trial with RGN-259 for the Treatment of Dry EyePrinter Friendly Version
08/15/11FirstPatients Enrolled in RegeneRx's Phase 2 Dry Eye TrialPrinter Friendly Version
07/28/11RegeneRx Set to Begin Enrolling Phase 2 Dry Eye TrialPrinter Friendly Version
06/13/11RegeneRx to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference On June 16Printer Friendly Version
06/08/11British, U.S., and Chinese Researchers Report that TB4 can Transform Resident Adult Heart Stem Cells into New Heart MusclePrinter Friendly Version
06/06/11Researchers Report New Data on TB4's Ability to Reduce Heart Attack DamagePrinter Friendly Version
06/01/11Researcher Reports that RegeneRx's Thymosin Beta 4 Can Trigger Maturation of Brain Stem CellsPrinter Friendly Version
Receive E-mail AlertsE-mail Alerts
 Upcoming Events
There are currently no events scheduled.
 Past Events
DateTitle
09/13/11 2:00 p.m. ET
ReGeneRx Biopharmaceuticals Inc at Rodman and Renshaw Global Investment Conference
LocationNew York, NY
02/15/11 10:30 a.m. ET
RegeneRx Biopharmaceuticals, Inc. at Biotechnology Industry Organization (BIO) CEO & Investor Conference
LocationNew York, NY
09/10/09 12:30 p.m. ET
RegeneRx Biopharmaceuticals, Inc. at Rodman & Renshaw Annual Global Investment Conference
LocationNew York, NY
10/30/08 11:00 a.m. PT
RegeneRx Biopharmaceuticals, Inc. at 7th Annual BIO Investor Forum
LocationSan Francisco, CA
04/02/08 3:00 p.m. ET
Q4 2007 RegeneRx Biopharmaceuticals, Inc. Earnings Conference Call
07/31/07 4:30 p.m. ET
RegeneRx Biopharmaceuticals, Inc. to Provide Update on Clinical Trials Program
06/07/07 10:00 a.m. ET
RegeneRx Biopharmaceuticals, Inc. Shareholders Meeting
Location2550 M Street, NW
, DC
04/02/07 3:00 p.m. ET
Q4 2006 RegeneRx Biopharmaceuticals, Inc. Earnings Conference Call
07/25/06 10:00 a.m. ET
RegeneRx Biopharmaceuticals, Inc. Annual General Shareholders Meeting
Location2550 M St, NW
Washington, DC
03/31/06 11:00 a.m. ET
Q4 2005 RegeneRx Biopharmaceuticals, Inc. Earnings Conference Call
03/31/06
Q4 2005 RegeneRx Biopharmaceuticals, Inc. Earnings Release

     
home|Contact Us|Resources|Site Map|
Search